Merck Sharp & Dohme

59 articles with Merck Sharp & Dohme

• 

  Merck-Orion Deal to Accelerate Therapy for Advanced Prostate Cancer

  7/13/2022

  ​​​​​​​The agreement with Merck brings $290 million upfront to Orion to access the latter's investigational candidate, ODM-208, for mCPRC and other related drugs.

• Symvivo Corporation Announces Collaboration with Merck

  1/5/2021

  Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Merck Sharp and Dohme Corp. Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s bacTRL™ platform technology for use in advancing delivery of oral vaccines. “We are excited to

• 

  Pink Slips Continue to Hit California Life Science Companies

  4/3/2019

  More job cuts are coming to California life science companies. Charles River Labs and Janssen are both making cuts as they reprioritize their businesses, according to Worker Adjustment and Retraining Notifications filed with the state of California.
• 

  Layoffs Hit California Biopharma Companies

  2/18/2019

  January was a rough month for many pharma employees in California, as several companies pulled the trigger on layoffs, or announced coming layoffs that will affect hundreds of employees.
• 

  A Look at 7 Upcoming and Recently Announced Biotech IPOs

  9/24/2018

  According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
• 

  Vivek Ramaswamy's Urovant Files for IPO to Raise $150 Million

  9/11/2018

  Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.

• Riffyn Forms Advisory Board of Biopharm and Biotech R&D Innovators

  5/31/2018

  Mr. Falholt previously served as the head of Novozymes R&D. Mr. Deshmukh most recently served as the Executive Director of R&D IT at Merck Sharp & Dohme.

• 

  Merck Laying Off 50 Employees in North Carolina

  12/14/2017

  Layoffs are expected to begin in February, according to reports.

• Pharma Giant Merck Sharp & Dohme Could Bring 600 New Jobs to Austin

  4/18/2017

• Proteros biostructures GmbH Forges $167 Million+ Cancer R&D Deal With Merck Sharp & Dohme

  11/23/2016

• Pharmaron LLC And Merck Sharp & Dohme Agree Deal To Acquire MSD’s UK Hoddesdon Site

  9/26/2016

• Merck Sharp & Dohme Accused Of Failing To Produce 1,800 Documents In Propecia Case

  8/12/2014

• Merck Sharp & Dohme to Present New Data at the 49th European Association for the Study of Diabetes Annual Meeting

  9/19/2013

• European Commission (EC) Gives Green Light to New 6-in-1 Childhood Vaccine From Sanofi Pasteur

  4/23/2013

• Asia Recalls Merck Sharp & Dohme's Contraceptive Devices

  3/26/2013

• Merck Sharp & Dohme to Cut 280 Jobs in Wicklow, Plans to Cease Operations by 2015

  3/7/2013

• Merck & Co., Inc. Release: ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy and Safety in Adult Patients Co-Infected With HIV-1 and Hepatitis B and/or C in a Subgroup Analysis at 240 Weeks

  11/14/2012

• Merck Sharp & Dohme Reports Positive Data From Late Fertility Drug Trial

  10/24/2012

• Merck Sharp & Dohme Opens New $21 Million Plant in Indonesia

  10/10/2012

• 90 Jobs to go at Merck Sharp & Dohme Plant in Cork

  10/4/2012